Not applicableEnded earlyNCT01346579What this trial is testingBiomarkers in Tissue Samples From Older Women With Breast CancerWho this might be right forBreast Cancer Alliance for Clinical Trials in Oncology 505
Early research (Phase 1)Study completedNCT00892736What this trial is testingVeliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous TherapyWho this might be right forBasal-Like Breast CarcinomaBRCA1 Mutation CarrierBRCA2 Mutation Carrier+14 more National Cancer Institute (NCI) 98
Large-scale testing (Phase 3)Looking for participantsNCT06382948What this trial is testingElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.Who this might be right forAdvanced Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+1 more MedSIR 300
Early research (Phase 1)Study completedNCT01104259What this trial is testingVeliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast CancerWho this might be right forEstrogen Receptor-negative Breast CancerHER2-negative Breast CancerHereditary Breast/Ovarian Cancer - BRCA1+6 more University of Washington 50
Not applicableUnknownNCT05814224What this trial is testingMonitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNAWho this might be right forHormone Receptor Positive Breast CarcinomaBreast NeoplasmsNeoplasms, Breast+4 more Centro di Riferimento Oncologico - Aviano 164
Large-scale testing (Phase 3)UnknownNCT03544762What this trial is testingCorrelation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 MutationWho this might be right forBreast Cancer National Taiwan University Hospital 60
Early research (Phase 1)Active Not RecruitingNCT02208375What this trial is testingMTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianWho this might be right forBRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial Adenocarcinoma+13 more M.D. Anderson Cancer Center 159
Testing effectiveness (Phase 2)Looking for participantsNCT05768139What this trial is testingFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsWho this might be right forBreast CancerSolid Tumors, Adult Eli Lilly and Company 880
Testing effectiveness (Phase 2)Study completedNCT04432454What this trial is testingEvaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationWho this might be right forMetastatic Breast Cancer Sermonix Pharmaceuticals Inc. 29
Testing effectiveness (Phase 2)Looking for participantsNCT05868226What this trial is testingPRE-ISPY Phase I/II Oncology Platform ProgramWho this might be right forHER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more QuantumLeap Healthcare Collaborative 280
Testing effectiveness (Phase 2)Looking for participantsNCT07222215What this trial is testingPhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)Who this might be right forEstrogen-receptor-positive Breast CancerMetastatic Breast CancerBreast Cancer+6 more Kristina A. Fanucci 297
Testing effectiveness (Phase 2)Study completedNCT01625286What this trial is testingInvestigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer PatientsWho this might be right forAdvanced or Metastatic Breast CancerER+ve Advanced or Metastatic Breast Cancer AstraZeneca 148
Very early researchLooking for participantsNCT04174352What this trial is testingFES Imaging to Optimize Tamoxifen for Metastatic Breast CancerWho this might be right forERα+ Breast CancerESR1 Gene Mutation University of Wisconsin, Madison 12
Early research (Phase 1)Study completedNCT01219699What this trial is testingBYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA GeneWho this might be right forAdvanced Solid Tumors With an Alteration of the PIK3CA GeneEstrogen Receptor Positive Breast Cancer Novartis Pharmaceuticals 221
Testing effectiveness (Phase 2)Looking for participantsNCT07558733What this trial is testingSapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast CancerWho this might be right forHR+ HER2- Breast Cancer Faeth Therapeutics 32
Early research (Phase 1)Active Not RecruitingNCT02432963What this trial is testingVaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyWho this might be right forAdult Solid NeoplasmBladder CarcinomaColon Carcinoma+14 more City of Hope Medical Center 11
Testing effectiveness (Phase 2)Looking for participantsNCT07766018What this trial is testingBridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer Stemline Therapeutics, Inc. 70
Not applicableLooking for participantsNCT06762483What this trial is testingIntegrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients,Who this might be right forBreast Cancer, Metastatic European Institute of Oncology 80
Testing effectiveness (Phase 2)Study completedNCT05054374What this trial is testingMirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor CancerWho this might be right forBreast CancerBreast Cancer Stage IVHER2-negative Breast Cancer+4 more Memorial Sloan Kettering Cancer Center 6
Testing effectiveness (Phase 2)Looking for participantsNCT06201234What this trial is testingEvaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerWho this might be right forHormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 Mutation+1 more GBG Forschungs GmbH 176